

JC970 U.S. PTO
07/24/01

07-25-01

EL475127479US

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	A070 US
First Inventor	Browning
Title	BAFF, Inhibitors Thereof and Their Use...
Express Mail Label No.	EL475127479US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 50]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 31]
5. Oath or Declaration [Total Pages]
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63 (d))
 (for continuation/divisional with Box 18 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney
11. English Translation Document (if applicable)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP)

of prior application No.: _____

Prior application information: Examiner _____


Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach Bar Code Label here)		<input type="checkbox"/> or <input type="checkbox"/> Correspondence address below
--	---	--	---

Name	Timothy P. Linkkila			
Address	BIOGEN, INC.			
	14 Cambridge Center			
City	Cambridge	State	MA	Zip Code
Country	USA	Telephone	(617) 679-3795	Fax (617) 679-2838

Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent)	40,702
Signature			Date 7/24/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

07/24/01
JC970 U.S.
PTO

475127479US

PTO/SB/17 (09-00)
Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 3,280)

Complte if Known

Application Number	not assigned yet
Filing Date	
First Named Inventor	Browning
Examiner Name	
Group Art Unit	
Attorney Docket No.	A070 US

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 02-2327
Deposit Account Name BIOGEN, INC.

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

Applicant claims small entity status. See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205 65 Surcharge - late filing fee or oath	
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	
139	130	139 130 Non-English specification	
147	2,520	147 2,520 For filing a request for ex parte reexamination	
112	920*	112 920* Requesting publication of SIR prior to Examiner action	
113	1,840*	113 1,840* Requesting publication of SIR after Examiner action	
115	110	215 55 Extension for reply within first month	
116	390	216 195 Extension for reply within second month	
117	890	217 445 Extension for reply within third month	
118	1,390	218 695 Extension for reply within fourth month	
128	1,890	228 945 Extension for reply within fifth month	
119	310	219 155 Notice of Appeal	
120	310	220 155 Filing a brief in support of an appeal	
121	270	221 135 Request for oral hearing	
138	1,510	138 1,510 Petition to institute a public use proceeding	
140	110	240 55 Petition to revive - unavoidable	
141	1,240	241 620 Petition to revive - unintentional	
142	1,240	242 620 Utility issue fee (or reissue)	
143	440	243 220 Design issue fee	
144	600	244 300 Plant issue fee	
122	130	122 130 Petitions to the Commissioner	
123	50	123 50 Petitions related to provisional applications	
126	240	126 240 Submission of Information Disclosure Stmt	
581	40	581 40 Recording each patent assignment per property (times number of properties)	
146	710	246 355 Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249 355 For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279 355 Request for Continued Examination (RCE)	
169	900	169 900 Request for expedited examination of a design application	

Other fee (specify) _____

Reduced by Basic Filing Fee Paid **SUBTOTAL (3) (\$ 0)**

SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Signature	Timothy P. Linkkila	Registration No. (Attorney/Agent)	40,702	Telephone (617) 679-3795
					Date 7/24/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. A070US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Biogen, Inc., et al.

Serial No.: Not assigned yet

Filing Date: Herewith

For: BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office via Express Mail Label EL475127479US addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: July 24, 2001 Signature: Patricia Hofstetter
Patricia Hofstetter

STATEMENT REGARDING SEQUENCE LISTING

Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSEQ 4.0.

The contents of the paper and computer readable copies are the same and, include no new matter, as required by 37 C.F.R. 1.821 (e). The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 7/24/01

Timothy P. Linkila

Timothy P. Linkila
Reg. No. 40,702
BIOMIN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-3795

F0102200-20070600

Docket No. A070US

Applicant: Biogen, Inc., et al.

Serial No.: Not assigned yet

Filing Date: Herewith

For: BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response

CERTIFICATE OF EXPRESS MAILING


I hereby certify that this correspondence (Utility Application Transmittal, Fee Transmittal (in duplicate), Utility Application including 40 pages of specification, 9 pages of claims, 1 page of Abstract and 31 sheets of drawings, Sequence listing statement, paper copy of sequence listing, sequence listing on diskette) are being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail Label No. EL475127479US in an envelope addressed to:

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

on

July 24, 2001

Date



Patricia Hofstetter

2007-07-24 17:56:50